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Abstract: Sex is a common baseline factor collected in studies that has the potential to be a prognostic
factor (PF) in several clinical areas. In recent years, research on sex as a PF has increased; however,
this influx of new studies frequently shows conflicting results across the same treatment or disease
state. Thus, systematic reviews (SRs) addressing sex as a PF may help us to better understand
diseases and further personalize healthcare. We wrote this article to offer insights into the challenges
we encountered when conducting SRs on sex as a PF and suggestions on how to overcome these
obstacles, regardless of the clinical domain. When carrying out a PF SR with sex as the index factor,
it is important to keep in mind the modifications that must be made in various SR stages, such as
modifying the PF section of CHARMS-PF, adjusting certain sections of QUIPS and extracting data on
the sex and gender terms used throughout the studies. In this paper, we provide an overview of the
lessons learned from carrying out our reviews on sex as a PF in different disciplines and now call on
researchers, funding agencies and journals to realize the importance of studying sex as a PF.
Keywords: sex; gender; prognosis; prognostic factor; systematic review; methods
1. Introduction
People are living longer, with one or more health problems; prognosis research is thus
vital for explaining and predicting future clinical outcomes in people with existing health
conditions. Prognosis research aims to summarize and predict relevant outcomes such as
death, recovery, recurrence, disability, or quality of life. In the past 10 years, research on
prognosis has rapidly increased [1–4] along with many novel studies and new methods
being developed. However, results from different studies are often contradictory, making
it difficult to assess a specific prognostic factor (PF). This is where systematic reviews
come into play. Nevertheless systematic reviews of PFs have received little attention by
scientists to date. In clinical medicine, we are starting to see a transition from a universal
medicine that has a one-size-fits-all approach to personalized medicine. Personalized
medicine is a unique individualized approach to treatment based on a patient’s diagnosis
and prognosis [5]. This intertwinement has led to theragnostics, which is the connection
of diagnosis and therapeutics addressed to people on an individual basis [6]. This novel
connection can provide better prognoses relying on specific features, i.e., PFs. Genetic
information plays an important role in theragnostics and pharmacogenetics—which is the
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study of how people respond differently to drug therapies based on their genes—and helps
to individually tailor treatments [7]. There are underlying genetic mechanisms to most sex
differences in disease [8], which suggests that sex is an excellent candidate as a PF.
Research on PFs is becoming more widespread, and its importance in clinical practice
is gradually being recognized. A PF “is any measure that, among people with a given
health condition (that is, a start point), is associated with a subsequent clinical outcome (an
endpoint)” [9]. Therefore, PFs can distinguish groups of people with a different average
prognosis. PF research has a wide variety of applications related to both clinical and public
health research [9]. For example, for many cancer patients, tumour grade at the time of
diagnosis is a prognostic factor, as each group of patients with the same tumour grade
should have broadly similar outcomes [3]. Also, a high body mass index (BMI) is a PF
for worse outcomes in patients diagnosed with COVID-19 [10]. Similarly, male sex is a
poor PF in non-small-cell lung cancer [11,12] and in gastric cancer, as females experience a
better survival rate [13]. On the other hand, female sex is a poor PF for mortality in acute
myocardial infarction [14,15]. Thus, minimal clinically relevant differences associated with
patients’ sex may have a great impact on the understanding of disease processes, the appli-
cability of the findings to specific patient groups, and the planning of future research [16].
Sex refers to the biological, genetic, and physiological processes that generally distinguish
females from males, while gender refers to the roles, relationships, behaviours, and other
traits that societies typically attribute to women, men, and people of diverse gender iden-
tities (e.g., transgender people) [17]. Sex is, with age, the most common baseline factor
collected in the context of randomized and non-randomized studies, regardless of whether
a study addresses a therapeutic, etiologic, diagnostic, or prognostic topic. Therefore, sex
has clearly the potential to be evaluated as a PF in almost all clinical areas [8,10,11]. This
issue is typically assessed in primary studies but is generally not a considered topic in
systematic reviews.
Systematic reviews (SRs) are the cornerstone of evidence-based medicine as they play
a major role in summarizing the available body of evidence and in identifying knowledge
gaps [18]. Accordingly, addressing sex-related findings in systematic reviews is important
to better guide clinical practice and tailor patient care to provide the optimal treatment
for different sexes. In contrast, in primary studies or systematic reviews, not considering
how meaningful such differences between sexes are can lead to poorer healthcare quality,
limiting the generalizability of study results and promoting inequities. In recent years,
research on sex as a PF has increased [1–4]; however, this influx of new studies frequently
shows conflicting results across the same treatment or disease state.
Sex differs from other PFs in that it is difficult to verify through tests and it generally
does not change over time. We have written this article to offer insights into the challenges
we encountered when conducting SRs on sex as a PF and to provide suggestions on how
to overcome these obstacles, regardless of the outcome or clinical domain. We carried out
two systematic reviews on sex as a PF. The first review studied the prognostic role of sex
on mortality outcomes in sepsis [19], while the second one looked at the role of sex in
the prognosis of patients with acute pulmonary embolism [20]. In the current paper, we
will comment on the lessons learned from these two reviews and, in the methodological
challenges section, we will present three SRs studying sex as a PF, providing examples
and making comparisons. Our objective is to discuss the methodological challenges we
encountered and reflect on the lessons learned in carrying out these reviews. Therefore,
future systematic reviewers will be able to learn from our experiences and use the same
framework whilst investigating sex as a prognostic factor. Primary researchers will also
be able to benefit from this paper, as they will understand the difficulties that reviewers
encounter when trying to synthesize this type of studies. For example, authors may become
aware of what terms should be used in abstracts and titles to maximize the likelihood of
their study being captured in review searches.
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2. Importance of Sex as a PF and Its Demarcation from Gender
Sex is a biological attribute that is associated with physical and physiological features in-
cluding gene expression, hormone function and reproductive and sexual anatomy [17,21,22].
Sex, typically assigned at birth based on the appearance of external genitalia, is defined
as female, male, intersex, etc. However, it is often mislabelled as gender. Sex and gender
are interconnected but vastly different. In comparison to sex, gender refers to the socially
constructed roles, behaviours and identities of female, male and gender-diverse people [22]
and to the terms men and women or boys and girls. Both sex and gender play roles as
prognostic factors in various illnesses (cardiovascular disease, sepsis, cancer) [15,19,23].
Therefore, it is important to distinguish between them when studying sex or gender as a
prognostic factor.
Many differences exist between the sexes, mostly due to genetics and hormones
(different levels of androgens and oestrogens). Many illnesses are characterized by a
higher incidence in one sex versus the other. For example, 99% of people diagnosed with
breast cancer are females [24]. In the same manner, four times more females than males
are diagnosed with osteoporosis [25]. Other illnesses will occur at the same rate in both
sexes, but they can manifest differently according to sex. For example, in schizophrenia,
the disease usually starts at an earlier age and with severer symptoms in males [26]. In
myocardial infarctions, again the first myocardial infarction is experienced at a younger
age by males than by females, and females tend to present with symptoms of nausea
and shortness of breath instead of the usual chest pain. These sex differences in disease
incidence and in diagnosing illness also predict differences in prognosis. Just as differences
have been found in the manifestation of myocardial infarction in females, it has also been
found that females tend to have poorer outcomes [27–29]. Similarly, in our review, we
found an independent prognostic impact of sex on mortality, although in this case the
certainty of evidence was very low [19].
Prognosis research has increased in the past decade, and the same can be said of
sex and gender research [1–4]. However, in general, there are not many SRs on PFs. For
example, when we searched the Cochrane database of systematic reviews, we found
three completed PF SRs [30–32]. In comparison to intervention reviews, which is the
more traditional review type with thousands of reviews completed, this is a novel area
of research and evidence synthesis. Thus, taking into consideration that so few reviews
have been published on PFs and sex separately and that both areas of research are rapidly
developing, it is understandable that there is a lack of SRs on sex as a PF. However, we did
find a few SRs evaluating the role of sex, such as Bougouin et al., Giuliano et al. and Kim
et al., in various illnesses, and thus we were able to compare and contrast these reviews
and review the methods that they used [33–35].
3. Methodological Challenges
3.1. Search and Selection
A search of reviews on sex as a PF retrieves thousands of references; therefore, it is
important to use a search filter. We added a sex and gender filter (“sex factors” OR “sex
distribution” OR “Sex characteristics” OR “Sex ratio” OR sex OR “women’s health” OR
“men’s health”) OR TITLE: (boy* OR male* OR girl* OR female* OR gender OR women
OR men OR sex) to the search strategy in an attempt to narrow down the search field. By
adding the filter, the number of studies retrieved from the searches was reduced by 20%.
In combination with searching electronic databases, we also hand-searched conferences.
For conferences on sex and gender, we found the congress “Organization for the study
of sex differences”. We hand-screened 8 years of abstracts from this conference and did
not retrieve any study that met all inclusion criteria. While retrieving unpublished studies
from conference abstracts is considered good practice in systematic review development, it
is important to consider the expected large number of results from the electronic database
searches. Thus, we encourage review authors to choose to extend their search to conference
proceedings based on their resource availability.
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When screening studies, both sexes must be included for a study to be eligible for
inclusion, as it is impossible to measure the prognostic significance of sex while only looking
at one sex. As mentioned above, sex refers to genotypic, phenotypic and physiological
characteristics, including chromosomes, gene expression, hormone levels and reproductive
and/or sexual anatomy [17]. In our reviews, we accepted any assessment of sex and
evaluated the appropriate use of the terms sex and gender when applicable. We were
aware that the terms ´sex´ and ´gender´ are poorly described and defined in the majority
of published articles. Thus, when no additional information was provided, if it was clear
that the authors were referring to sex but mistakenly used the terms for gender, we assumed
that the study was considering sex. If the authors explicitly stated that they evaluated the
social aspect, then we considered that they were evaluating gender and not sex.
3.2. Data Extraction
For data extraction, we used the CHARMS-PF (critical appraisal and data extraction
for systematic reviews of prediction modelling studies for prognostic factors) template [9].
CHARMS-PF is a checklist of key data to be extracted from primary PF studies. It is
based on additions and modifications of the original CHARMS data extraction sheet for
prediction modelling [36]. In the CHARMS-PF extraction sheet, there is a section created
for PFs (index and comparator factors). In this section, we extracted the PF definition and
method of measurement of the PF. We accepted any definition of sex (our PF of interest)
and any method of sex measurement given by the authors. The timing of PF measurement
does not matter when studying sex in primary studies or reviews, as it is not normally
a temporal variable that may change. We extracted information on the use of the terms
sex and gender in each study to evaluate if the terms were being used adequately in the
primary studies. These data are important to extract and take note of, as the lack of literacy
surrounding the terms for sex and gender should be highlighted in SRs.
Bougouin et al. did not use CHARMS for data extraction [33]. However, CHARMS,
is relatively new (2014) and was only published a year before the publication of this
review [36]. Thus, the authors may had previously planned their data extraction methods
in a protocol and did not change them. However, they did extract the adjusted data, though
they did not extract many data on gender, their prognostic factor of interest. Giuliano et al.
did not mention the use of CHARMS but created their own data extraction template [35].
Kim et al. also did not use CHARMS, as it was not yet published [34].
3.3. Risk of Bias Assessment
A critical step in carrying out a systematic review is assessing the risk of bias of the
included studies. Tools used to measure quality are ROB and ROB2 for randomized trials
and PROBAST for prediction model studies [37–40]. To assess the risk of bias in PF studies,
the “Quality in Prognosis Studies” (QUIPS) tool was created [41,42]. The tool consists
of several prompting questions within six different domains, each domain being judged
on a three-grade scale. Hayden et al. determined six key domains for the risk of bias
appraisal included in PF studies: study participation, study attrition, PF measurement,
other prognostic factor adjustment, outcome measurement and analysis and reporting [42].
We used an amendment to the QUIPS tool proposed by Aldin and colleagues [30]
using four categories (low, moderate, high and unclear risk) instead of the initial three
categories (low, moderate and high). In SRs of sex as a PF, the unclear category may be
especially relevant, since some signalling items of QUIPS, such as those related to PF
domains with a high likelihood of lack of sex definition, have a limited value for the
assessment and rating. Therefore, rating as unclear risk may be the fairest alternative.
Following on from the rating amendment, we also made some slight modifications to the
QUIPS sections to adapt it for sex as a PF, which are highlighted in Table 1. Some items
were particularly hard to differentiate, and a learning phase was required to increase the
interrater agreement.
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Table 1. QUIPS modifications for studying sex as a prognostic factor.
Domains QUIPS QUIPS Modified for Sex as PF Comments
1. Study participation Description of the baseline studysample
Baseline number and
characteristics of participants by
sex are clearly described and
reported separately for males and
females
The regular QUIPS refers to a
description of the baseline sample
in general (both sexes combined);
however, we specified that it was
necessary to have the participants
characteristics described by sex.
Example: Females (N): race of
females (N), obesity in females
(N). Males (N): race of males (N),
obesity in males (N).
2. Study attrition Adequate description ofparticipants lost to follow-up
Key characteristics of participants
lost to follow-up are provided
separately for males and females
The key characteristics of the
lost-to-follow-up participants
must be recorded by sex. N of
females and N of males per
characteristic. However, this was
never reported.
3. Prognostic factor measurement Clear definition or description ofthe PF
Clear definition or description of
sex
The authors must provide an
adequate definition for the
prognostic factor, in this case
sex 1.
Adequately valid and reliable
method of measurement Not applicable
We do not anticipate specific sex
measurement for this type of
research question.
Continuous variables reported or
appropriate cut points used Not applicable
Sex measurement is not a
continuous variable.
Same method and setting of
measurement used in all study
participants
Not applicable
We do not anticipate method and
setting measurement for this type
of research question.
Adequate proportion of the study
sample had complete data Not applicable
We do not anticipate missing data
of sex measurement for this type
of research question.
Appropriate methods of
imputation were used for missing
data
Not applicable
We do not anticipate missing data
of sex measurement for this type
of research question.
4. Outcome measurement No differences in this domain.
5. Adjustment for other
prognostic factors No differences in this domain.
6. Statistical analysis and
reporting No differences in this domain.
1 We considered an adequate definition as listing any of the following: sex for biological characteristics; gender for socially constructed
roles, behaviours, and identities; females or males for sex; women or men for gender.
In contrast, Bougouin et al. did not use QUIPS for quality assessment, but again this
could be due to the short time frame between QUIPS and the review being published [33].
Giuliano et al. used QUIPS to assess the risk of bias of the included studies; however, they
did not mention any modifications being made to the tool [35]. Kim et al. did not use
QUIPS in their assessment of risk of bias, as it was not yet published [34].
3.4. Data Analysis
The studies incorporated in a systematic review of sex as a PF need to be similar in
terms of population (ages, ethnicity, etc.), index factor measurement (sex) and outcome
measurement (how the outcomes are measured, for example, mortality in 30 days, 90 days,
etc.): a meta-analysis must combine the results from sufficiently homogenous individual
studies to provide a meaningful pooled prognostic effect estimate. If the studies are
not homogenous in design, we may carry out a subgroup analysis or meta-regression.
Studies may report the crude association between PF, sex, and the outcome or the adjusted
association, where one adjusts for the contribution of other PFs compared to the index
factor (here, sex). However, we did not require the consideration of the complete core
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set of additional PFs. In our experience, if the researchers adjusted for at least one of
our pre-defined confounding factors, then the study was valid for inclusion in the review
and the meta-analysis. Deciding the pre-defined confounding factors was complicated,
as sex is a factor that is present from birth; therefore, it is complex to define what is a
confounding factor of sex. To make a list of the most important confounding factors, we
created a Delphi panel of reviewers and clinicians to decide on which factors to include.
Our data extraction and risk of bias assessments considered the confounding factors that
were measured, controlled for (by the study design) and adjusted for (in the analysis).
An additional part of the analysis in reviews studying sex as a PF is to analyse the
sex/gender terminology used. To judge if the terms sex and gender were used correctly
in the primary studies, we conducted a frequency analysis of the results. In our SR on
sex as PF in patients with sepsis, we included 13 studies [19]. No primary study included
in our review defined sex correctly. Twelve of the included studies in our review had an
inadequate use of sex and gender terms, using all the terms interchangeably throughout
the study. The correct usage of terms was unclear in the remaining study, as it used the
term gender and all the related terminology for gender; however, from the study context, it
could be presumed that the study authors were in fact referring to sex [43].
In some SRs, there are discrepancies and interchangeability of the sex and gender
terms. The correct terms for sex are male and female, and those for gender are boy, girl,
man or woman. Many published reviews use the word gender when referring to sex, thus
making it confusing for readers. Authors feel that they are being repetitive and do not
realise that sex and gender are two distinct terms. For example, in Bougouin et al. and
Kim et al., the authors use the terms gender, men and women consistently but in reality,
they are discussing topics related to sex, not gender [33,34]. In Kim et al., the authors state
“women tend to have smaller coronary arteries than men” [34]. This is a sex difference, not
a gender difference and should instead read “female patients tend to have . . . than male...”.
Likewise, Giuliano et al. talk about sex differences whilst referring to men and women. In
other parts of the paper, they also use the terms male and female, thus making their usage
of the terminology incorrect and inconsistent [35].
4. Concluding Remarks
The role of sex in human health and medical research continues to be understudied,
as sex-based medicine is often viewed as a specialist niche instead of being central to all
medical research [16]. We must bring sex- and gender-based analysis to the forefront of
research and base future research around it. Systematic reviews evaluating the role of sex
as a PF fosters rigorous, reproducible, inclusive and responsible science.
When carrying out a PF SR with sex as the index factor, it is important to keep in
mind the adaptations that must be made in various SR stages. This is outlined in Table 2
below and includes modifying the PF section of CHARMS-PF, adjusting certain sections
of QUIPS and extracting data on the terms sex and gender used throughout the studies.
The lack of literacy regarding the sex and gender terms needs to be addressed, as this is a
widespread problem among researchers. It is especially important that researchers wishing
to study and publish sex and gender research understand the differences between these
concepts and use the correct terminology. This lack of understanding can have serious
implications in prognosis research, such as creating confusion among investigators and the
general public.
There are methods available to rigorously synthesize the role of sex as a PF. We hope
to see more systematic reviews of this kind in the future. In this paper, we have provided
an overview of the lessons we learned from carrying out our reviews on sex as a PF
in different disciplines and we now call on researchers, funding agencies, journals and
research institutions to acknowledge the importance of studying sex as a PF. Realizing this
importance is a critical step in the right direction towards precision medicine that will help
reduce health inequities and benefit both males and females alike.
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Table 2. Summary of challenges and solutions in a systematic review evaluating the role of sex as a
prognostic factor.
Challenge Solution
1. Search and selection Too many references retrievedin the search.
Add a sex and gender search
filter to the search
2. Data extraction
Sections of CHARMS-PF not
totally compatible with sex as
a prognostic factor (PF)
Take the following into
consideration:
• Accept any definition of
sex and any method of
sex measurement given
by authors
• Timing of PF
measurement is not
important, as sex is not
normally a temporal
variable that may change
• Extract data on the use of
the terms sex and gender
3. Risk of Bias Sections of QUIPS notcompatible with sex as a PF
Specific modifications in
QUIPS tool as listed in Table 1
4. Data analysis Deciding the confoundingfactors for sex as a PF
Delphi panel (expert input) to
aid in this decision-making
process




Analyse the sex and gender
terminology used in primary
studies
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